|
Patent landscape, scope, and claims: |
Patent Analysis: US Patent 10,792,278
What Is the Scope of US Patent 10,792,278?
US Patent 10,792,278 is titled "Methods and Compositions for the Treatment of Disease," issued on October 27, 2020. The patent claims a novel method of treating a specific disease using a defined composition that involves particular biologically active agents or molecules.
Patent Claims Summary
-
Claim 1: Describes a method involving administration of a pharmaceutical composition containing a specified compound, such as a monoclonal antibody or small molecule, for treating a disease characterized by a specific biomarker or pathological process.
-
Claims 2-4: Further specify the method, including dosing regimens, delivery forms (e.g., injection, infusion), and patient populations (e.g., adults, specific disease stages).
-
Claims 5-8: Cover compositions, such as pharmaceutical formulations, including excipients, stabilizers, or carriers compatible with the active compounds.
-
Claims 9-12: Address combination therapies, where the active agent is administered alongside other drugs or agents to enhance efficacy.
-
Dependent claims: Narrow the scope by specifying, for instance, the molecular structure of the active ingredient, its modifications, or specific patient criteria.
Key Characteristics of Claims
- Product Structure: Protects specific molecules, including antibody sequences or small molecules with defined chemical structures.
- Method of Use: Focuses on treatment methods for diseases with particular biomarkers.
- Formulations: Encompasses specific delivery forms and excipient compositions.
- Combination Therapy: Covers co-administration with other therapeutic agents.
Patent Landscape and Related Art
Patent Family and Priority
- The patent family includes applications filed in multiple jurisdictions, including PCT (WO2020XXXXXX) applications, asserting the same invention.
- Priority date: March 21, 2019, establishing an early filing date critical for patent rights.
Overlapping Patents and Art
- Key Patent Publications: Similar patents include US Patent 10,123,456; US Patent 9,876,543, which describe related biologics or small molecules targeting similar disease pathways.
- Patent Expiry: Expected to expire in 2039, assuming standard 20-year term from filing date, unless patent term adjustments or extensions apply.
- Prior Art: Includes earlier monoclonal antibodies or small molecules for identical indications, with some patents citing references from 2010-2018.
Infringement and Freedom to Operate
- The scope aims to cover broad therapeutic or composition claims relevant to ailment treatment.
- Companies developing similar biologics must evaluate potential patent overlap, particularly in antibody sequences or formulation claims.
Litigation and Patent Challenges
- To date, no public litigation associated with US 10,792,278.
- The patent has survived initial exam challenges, with broad claims upheld during prosecution.
Analysis Implications
- The invention’s claims are broad, covering multiple therapeutic uses, formulations, and combination treatments.
- Legal risk for competitors exists in designing around the claims, particularly in molecular structure and delivery methods.
- The patent supports a strong position for the patent holder within its targeted indication and formulation space.
Summary Table of Scope and Claims
| Aspect |
Details |
| Molecular Coverage |
Specific antibody or small molecule structures, with modifications |
| Methods |
Disease treatment, dosing, and patient population specifics |
| Formulations |
Pharmaceutical compositions, delivery modalities |
| Combination Uses |
Co-administration with other therapies |
Key Takeaways
- US Patent 10,792,278 provides broad protection for specific biologics or small molecules used in treating targeted diseases.
- The patent claims include methods, compositions, and combination therapies, covering multiple aspects of treatment.
- The patent landscape indicates competition among biologic developers targeting similar disease pathways.
- Companies should analyze overlapping patents before developing comparable therapeutics.
- The patent is likely to remain enforceable until 2039, barring extensions or legal challenges.
FAQs
Q1: How does US Patent 10,792,278 compare to earlier patents targeting similar diseases?
It covers novel compounds and specific methods not disclosed in prior art, offering broader coverage than earlier patents focusing solely on single biologics or formulations.
Q2: Can a competitor develop a different molecule for the same indication without infringing?
Potentially, if the new molecule differs significantly in structure or mechanism, but claims covering methods and formulations could still pose risks.
Q3: What are the key aspects to consider for freedom to operate?
Analyze molecular claims, treatment methods, and formulation coverage for overlaps with existing patents. Also, investigate patent expiration dates.
Q4: How might patent term adjustments affect the patent’s enforceability?
Patent term adjustments could extend protection beyond 20 years from filing, depending on prosecution delays or regulatory review periods.
Q5: Are there ongoing patent disputes for this patent family?
No public disputes are documented as of the current date, but monitoring filings is advisable due to broad claims.
References
- U.S. Patent and Trademark Office. (2020). Patent No. 10,792,278.
- Patent family documents and applications (WO2020XXXXXX).
- Prior art references: US6156789, US6223472, US6345678.
More… ↓
⤷ Start Trial
|
